Kirsten Raun
Vice President - Scientific Novo Nordisk
With over 30 years at Novo Nordisk, I have led pioneering research in obesity and amylin biology. I have spearheaded studies demonstrating that a longacting amylin analogues deserve an important place in future treatment of metabolic diseases. Establishing pre-clinical models, understanding mode of action, translational aspects, biomarkers and ensure clinical trial designs capture newest knowledge to optimize understanding, and efficacy is always on top of my agenda. I am passionate about amylin and my commitment lies in advancing scientific excellence to develop innovative treatments for obesity and diabetes, leveraging deep expertise in appetite regulation and metabolic disorders.
Seminars
Wednesday 2nd December 2026
Translating Dual GLP-1/Amylin Agonism into Meaningful Glycaemic Control & Weight Loss: Lessons from Zenagamtide
11:30 am
- Examine the Phase II dose-response findings for once-weekly zenagamtide, including HbA1c reductions of up to 1.71 percentage points and body-weight loss of up to 14.6% at 36 weeks, to assess the clinical potential of combining GLP-1 and amylin receptor agonism within a single molecule
- Explore how dose escalation, receptor balance and exposure influenced efficacy and gastrointestinal tolerability, enabling developers to refine therapeutic windows and make more informed dose-selection decisions for next-generation co-agonists
- Translate the findings into future development strategy, from identifying the patient populations most likely to benefit to determining how dual GLP-1/amylin assets can differentiate from established incretins as zenagamtide advances toward Phase III development
